Cargando…
PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428964/ http://dx.doi.org/10.1097/01.HS9.0000975992.31213.35 |
| _version_ | 1785090597346869248 |
|---|---|
| author | Hirano, Mitsuhito Yoshida, Kikuaki Hirano, Kei Teramoto, Yukako Tamba, Mikako Yamauchi, Nobuhiko Shirouchi, Yuko Ishihara, Yuko Asai, Hiroaki Mishima, Yuko Takeuchi, Kengo Maruyama, Dai |
| author_facet | Hirano, Mitsuhito Yoshida, Kikuaki Hirano, Kei Teramoto, Yukako Tamba, Mikako Yamauchi, Nobuhiko Shirouchi, Yuko Ishihara, Yuko Asai, Hiroaki Mishima, Yuko Takeuchi, Kengo Maruyama, Dai |
| author_sort | Hirano, Mitsuhito |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428964 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104289642023-08-17 PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES Hirano, Mitsuhito Yoshida, Kikuaki Hirano, Kei Teramoto, Yukako Tamba, Mikako Yamauchi, Nobuhiko Shirouchi, Yuko Ishihara, Yuko Asai, Hiroaki Mishima, Yuko Takeuchi, Kengo Maruyama, Dai Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428964/ http://dx.doi.org/10.1097/01.HS9.0000975992.31213.35 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Hirano, Mitsuhito Yoshida, Kikuaki Hirano, Kei Teramoto, Yukako Tamba, Mikako Yamauchi, Nobuhiko Shirouchi, Yuko Ishihara, Yuko Asai, Hiroaki Mishima, Yuko Takeuchi, Kengo Maruyama, Dai PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES |
| title | PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES |
| title_full | PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES |
| title_fullStr | PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES |
| title_full_unstemmed | PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES |
| title_short | PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES |
| title_sort | pb2317: polatuzumab vedotin plus bendamustine and rituximab therapy in relapsed or refractory diffuse large b-cell lymphoma: a single-institution experience focusing on detailed assessment of toxicities |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428964/ http://dx.doi.org/10.1097/01.HS9.0000975992.31213.35 |
| work_keys_str_mv | AT hiranomitsuhito pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT yoshidakikuaki pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT hiranokei pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT teramotoyukako pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT tambamikako pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT yamauchinobuhiko pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT shirouchiyuko pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT ishiharayuko pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT asaihiroaki pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT mishimayuko pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT takeuchikengo pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities AT maruyamadai pb2317polatuzumabvedotinplusbendamustineandrituximabtherapyinrelapsedorrefractorydiffuselargebcelllymphomaasingleinstitutionexperiencefocusingondetailedassessmentoftoxicities |